Status:
COMPLETED
Glucagon in MODY (Maturity Onset Diabetes of the Young)
Lead Sponsor:
University of Oxford
Collaborating Sponsors:
Oxford University Hospitals NHS Trust
Conditions:
MODY1
MODY3
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to determine whether fasting and post-prandial glucagon secretion is suppressed by gliclazide in patients with HNF1-/4-alpha MODY. Participants will undergo an oral glucose to...
Eligibility Criteria
Inclusion
- Diagnosis of HNF1-alpha or HNF4-alpha MODY.
- Currently on gliclazide treatment
Exclusion
- Currently taking any anti-diabetic medication other than gliclazide and metformin
- Oral steroid treatment 30 days prior to the start or at any time during the study period.
- Known malignancy or any other condition or circumstance which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol.
- Felt to be unsuitable to participate in the study in the opinion of the Chief Investigator.
- Currently participating in a clinical trial involving an anti-diabetic medication
Key Trial Info
Start Date :
July 3 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03246828
Start Date
July 3 2017
End Date
August 1 2022
Last Update
August 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Unit, OCDEM, Churchill Hospital
Oxford, Oxfordshire, United Kingdom, OX3 7LE